Order in --:--:-- → ships today
Retatrutide
>99%
HPLC · Lot RETA-360516
Triple incretin agonist (GLP-1 / GIP / GCG)

Retatrutide

Retatrutide (LY3437943) — Triple GLP-1 / GIP / glucagon receptor agonist

Verify this batchHPLC + MS
LotRETA-360516
TestedApr 2026
Purity>99%
Dosage
Quantity
In stock — --:--:-- to ship today
1
$79.00
Overview

Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist designed by Eli Lilly. The molecule simultaneously engages the GLP-1, GIP, and glucagon receptors — adding glucagon-receptor activation to the dual GLP-1/GIP profile of tirzepatide. A C20 fatty diacid is conjugated to enable non-covalent albumin binding and extend the half-life to roughly 6 days. In SURMOUNT and Phase 2 obesity trials, retatrutide produced the largest body-weight reductions reported to date for any peptide agent, making it one of the most closely watched molecules in current metabolic research.

Mol. weight4731.43
Purity≥99.0%
FormLyophilized powder
Storage−20°C, dry, dark

Questions

Each vial contains lyophilized peptide powder at the labeled dosage. No solvents, fillers, or preservatives.

Research use only. Not for human or veterinary use.